STOCK TITAN

Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Aprea Therapeutics will host a KOL event on October 31, 2023, featuring Dr. Fiona Simpkins and Dr. Timothy A. Yap. They will discuss treatments and investigational drugs for patients with advanced solid tumors. Aprea will also discuss its Phase 1/2a study evaluating ATRN-119 and its pre-clinical WEE1 inhibitor, ATRN-1051. A live Q&A session will follow the presentations.
Positive
  • Aprea Therapeutics will host a KOL event to discuss treatments and investigational drugs for patients with advanced solid tumors, potentially indicating progress in their research and development efforts.
Negative
  • None.

Event featuring Fiona Simpkins, M.D. and Timothy A. Yap, MBBS, PhD, FRCP to take place on October 31, 2023 at 11:00 am ET

DOYLESTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced it will host a KOL event on Tuesday, October 31, 2023 at 11:00 am ET. The program will feature Dr. Fiona Simpkins, Perelman School of Medicine, University of Pennsylvania, and Dr. Timothy A. Yap, University of Texas MD Anderson Cancer Center, who will discuss the current landscape of treatments and investigational drugs for patients with advanced solid tumors and their role in tumor suppression.

The Aprea Therapeutics team will discuss the Phase 1/2a study evaluating its lead program of a highly potent and selective macrocyclic inhibitor of ataxia telangiectasia and Rad3-related (ATR), ATRN-119, in patients with advanced solid tumors having mutations in defined DDR genes. The event will also highlight Aprea’s pre-clinical WEE1 inhibitor, ATRN-1051, with IND filing anticipated by the end of 2023, including the clinical development strategy for the study of ATRN-1051

A live question and answer period will follow the presentations. The session will be available for replay on the News and Events portion of the Investor Relations section of the company’s website. To register for the event, please click here.

About Fiona Simpkins, M.D.
Dr. Fiona Simpkins is a Professor in the Division of Gynecology Oncology and Department of OB-GYN at the University of Pennsylvania. She is Director of Preclinical Drug Development for the Ovarian Cancer Research Center and a member on the Phase I/Developmental Therapeutics Committee for Gynecological Cancers for the NRG Cooperative Group. Dr. Simpkins completed her OB-GYN residency at Johns Hopkins University and Gynecology Oncology Surgical fellowship at the Cleveland Clinic Foundation. She is board certified in GOB-GYN and Gynecology Oncology. a surgeon and specializes in gynecological cancer surgeries. Her laboratory’s focus is developing strategies to circumvent drug resistance in gynecological cancers. Dr. Simpkins completed a Cancer Research Training in basic science focusing on ovarian cancer signal transduction at the National Cancer Institute. She completed a post-doctoral fellowship at the University of Miami studying ant-estrogen resistance in ovarian cancer. Dr. Simpkins is also a principal investigator for early phase ovarian cancer clinical trials evaluating novel therapies emanating from her laboratory.

About Timothy A. Yap, MBBS, PhD, FRCP
Dr. Timothy Yap is a Medical Oncology Physician-Scientist and Professor based at the University of Texas MD Anderson Cancer Center. He is a Professor in the Department for Investigational Cancer Therapeutics (Phase I Program), and the Department of Thoracic/Head and Neck Medical Oncology. Dr. Yap is Vice President and Head of Clinical Development in the Therapeutics Discovery Division, a drug discovery biopharmaceutical division where drug discovery and clinical translation are seamlessly integrated. He is also the Associate Director of Translational Research in the Institute for Personalized Cancer Therapy, which is an integrated research and clinical trials program aimed at implementing personalized cancer therapy and improving patient outcomes. Dr. Yap’s main research focuses on the first-in-human and combinatorial development of molecularly targeted agents and immunotherapies, and their acceleration through clinical studies using novel predictive and pharmacodynamic biomarkers. His main interests include the targeting of the DNA damage respons (DDR) with novel therapeutics, such as ATR, PARP1, WEE1, POLQ, USP1, PARG, CHK1, ATM, and DNA-PK inhibitors, next generation CDK4 and CDK1-selective inhibitors, YAP/TEAD inhibitors, as well as the development of novel immunotherapeutics. Prior to his current position, Dr. Yap was a Consultant Medical Oncologist at The Royal Marsden Hospital in London, UK and National Institute for Health Research BRC Clinician Scientist at the Institute of Cancer Research, London, UK.

About Aprea
Aprea Therapeutics, Inc. is a clinical stage biopharmaceutical company headquartered in Doylestown, Pennsylvania, focused on precision oncology through synthetic lethality. The Company’s lead program is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. Our oral, small molecule WEE1 inhibitor is being advanced to IND submission. For more information, please visit the company website at www.aprea.com.

The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.

Forward-Looking Statement
Certain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended related to our study analyses, clinical trials, regulatory submissions, and projected cash position. We may, in some cases use terms such as “future,” “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “targeting,” “confidence,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team and on information currently available to management that involve risks, potential changes in circumstances, assumptions, and uncertainties. All statements contained in this press release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, including timing considerations and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are submits to risks and uncertainties including, without limitation, risks related to the success, timing and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials, futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results including, without limitation, any preclinical results or data, which are not necessarily indicative of the final results of our ongoing clinical trials, and the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to update such forward-looking statement for any reason, except as required by law.

Investor Contact:

Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com


FAQ

When will the KOL event hosted by Aprea Therapeutics take place?

The KOL event will take place on October 31, 2023.

Who are the featured speakers at the event?

The featured speakers at the event are Dr. Fiona Simpkins and Dr. Timothy A. Yap.

What topics will be discussed at the event?

The event will cover the current landscape of treatments and investigational drugs for patients with advanced solid tumors, as well as Aprea's Phase 1/2a study on ATRN-119 and the pre-clinical development of ATRN-1051.

Will there be a Q&A session during the event?

Yes, there will be a live question and answer period following the presentations.

Where can I register for the event?

You can register for the event on the company's website.

Aprea Therapeutics, Inc.

NASDAQ:APRE

APRE Rankings

APRE Latest News

APRE Stock Data

17.61M
4.40M
11.75%
43.85%
0.28%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
DOYLESTOWN